Study of Treatments for MRD-Positive Acute Myeloid Leukemia AML in Patients 14 Years and Older Evaluating Effectiveness and Safety of Various Drug Combinations and Genetic Mutation-Targeted Therapies

What this Trial Is About

Researchers are investigating treatments for patients aged 14 years or older with acute myeloid leukemia AML, excluding subtype M3, who have achieved complete remission but remain positive for minimal residual disease MRD. The study focuses on evaluating the effectiveness and safety of various drug regimens for these MRD-positive AML patients, aiming to improve relapse-free survival and overall survival rates. The trial involves multiple treatment combinations that include chemotherapy, targeted small molecule drugs, demethylation agents, and liposome drugs. Specific drug regimens vary by patient genetic mutations and may include drugs such as Ivosidenib, Gilteritinib, Venetoclax, Avapritinib, Daunorubicin, Cytarabine, Azacitidine, and others. Treatments are administered in cycles with detailed dosing schedules, and hematopoietic stem cell transplantation may occur at any time during treatment as determined by the doctor. Participants will be monitored for relapse-free survival up to six months and overall survival until death. The study also evaluates measurable residual disease, the proportion of patients turning MRD negative, cumulative relapse rates, and adverse events over a period extending up to two years. Assessments include laboratory tests and genetic analyses to track disease status and treatment safety throughout the trial duration, which is expected to complete by late 2028.

MRD-positive AML Clinical Study